Management of acute and chronic migraine

Gianluca Coppola, Jean Schoenen

Research output: Contribution to journalArticle

Abstract

Purpose of review: We highlight the recent clinical trials for the management of acute and chronic migraine. Recent findings: In women with menstrual migraine, triptans seem to be well tolerated irrespective of whether or not patients are taking oestrogen-containing contraceptives or have comorbidities that indicate increased cardiovascular risk. The new acute drug, telcagepant, a calcitonin gene-related peptide (CGRP) antagonist, is safe for long-term use (up to 18 months) in migraine patients with stable coronary artery disease in whom the use of triptans is not advisable. From the pooled analysis of the two Phase III Research Evaluating Migraine Prophylaxis Therapy studies of onabotulinumtoxin A (BOTOX) in chronic migraineurs, it clearly emerged that efficacy increases overtime (up to 56 weeks) and paralleled self-perceived improvement in quality of life. Effectiveness was also observed in patients with severely disabling headaches, who met criteria for triptan abuse and were refractory to several prophylactic treatments. Finally, combination of preventive pharmacological agents with different action mechanisms may be the next frontier in therapeutic advancements for treating migraine. Summary: Although triptans are safe and well tolerated, CGRP antagonists may be an option for nonresponsive patients or those in whom the use of triptans is not advisable. New drugs and combinations of old therapeutic options may help patients with severe forms of headache.

Original languageEnglish
Pages (from-to)177-182
Number of pages6
JournalCurrent Opinion in Supportive and Palliative Care
Volume6
Issue number2
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Tryptamines
Migraine Disorders
Calcitonin Gene-Related Peptide
Headache
Drug Combinations
Therapeutics
Contraceptive Agents
Comorbidity
Coronary Artery Disease
Estrogens
Quality of Life
Clinical Trials
Pharmacology
Research
Pharmaceutical Preparations

Keywords

  • Acute
  • Migraine
  • Preventive
  • Review
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)
  • Critical Care and Intensive Care Medicine
  • Oncology(nursing)

Cite this

Management of acute and chronic migraine. / Coppola, Gianluca; Schoenen, Jean.

In: Current Opinion in Supportive and Palliative Care, Vol. 6, No. 2, 06.2012, p. 177-182.

Research output: Contribution to journalArticle

Coppola, Gianluca ; Schoenen, Jean. / Management of acute and chronic migraine. In: Current Opinion in Supportive and Palliative Care. 2012 ; Vol. 6, No. 2. pp. 177-182.
@article{02073dc634184d5e8c4b6cff6cdb1e76,
title = "Management of acute and chronic migraine",
abstract = "Purpose of review: We highlight the recent clinical trials for the management of acute and chronic migraine. Recent findings: In women with menstrual migraine, triptans seem to be well tolerated irrespective of whether or not patients are taking oestrogen-containing contraceptives or have comorbidities that indicate increased cardiovascular risk. The new acute drug, telcagepant, a calcitonin gene-related peptide (CGRP) antagonist, is safe for long-term use (up to 18 months) in migraine patients with stable coronary artery disease in whom the use of triptans is not advisable. From the pooled analysis of the two Phase III Research Evaluating Migraine Prophylaxis Therapy studies of onabotulinumtoxin A (BOTOX) in chronic migraineurs, it clearly emerged that efficacy increases overtime (up to 56 weeks) and paralleled self-perceived improvement in quality of life. Effectiveness was also observed in patients with severely disabling headaches, who met criteria for triptan abuse and were refractory to several prophylactic treatments. Finally, combination of preventive pharmacological agents with different action mechanisms may be the next frontier in therapeutic advancements for treating migraine. Summary: Although triptans are safe and well tolerated, CGRP antagonists may be an option for nonresponsive patients or those in whom the use of triptans is not advisable. New drugs and combinations of old therapeutic options may help patients with severe forms of headache.",
keywords = "Acute, Migraine, Preventive, Review, Treatment",
author = "Gianluca Coppola and Jean Schoenen",
year = "2012",
month = "6",
doi = "10.1097/SPC.0b013e3283521dc3",
language = "English",
volume = "6",
pages = "177--182",
journal = "Current Opinion in Supportive and Palliative Care",
issn = "1751-4258",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Management of acute and chronic migraine

AU - Coppola, Gianluca

AU - Schoenen, Jean

PY - 2012/6

Y1 - 2012/6

N2 - Purpose of review: We highlight the recent clinical trials for the management of acute and chronic migraine. Recent findings: In women with menstrual migraine, triptans seem to be well tolerated irrespective of whether or not patients are taking oestrogen-containing contraceptives or have comorbidities that indicate increased cardiovascular risk. The new acute drug, telcagepant, a calcitonin gene-related peptide (CGRP) antagonist, is safe for long-term use (up to 18 months) in migraine patients with stable coronary artery disease in whom the use of triptans is not advisable. From the pooled analysis of the two Phase III Research Evaluating Migraine Prophylaxis Therapy studies of onabotulinumtoxin A (BOTOX) in chronic migraineurs, it clearly emerged that efficacy increases overtime (up to 56 weeks) and paralleled self-perceived improvement in quality of life. Effectiveness was also observed in patients with severely disabling headaches, who met criteria for triptan abuse and were refractory to several prophylactic treatments. Finally, combination of preventive pharmacological agents with different action mechanisms may be the next frontier in therapeutic advancements for treating migraine. Summary: Although triptans are safe and well tolerated, CGRP antagonists may be an option for nonresponsive patients or those in whom the use of triptans is not advisable. New drugs and combinations of old therapeutic options may help patients with severe forms of headache.

AB - Purpose of review: We highlight the recent clinical trials for the management of acute and chronic migraine. Recent findings: In women with menstrual migraine, triptans seem to be well tolerated irrespective of whether or not patients are taking oestrogen-containing contraceptives or have comorbidities that indicate increased cardiovascular risk. The new acute drug, telcagepant, a calcitonin gene-related peptide (CGRP) antagonist, is safe for long-term use (up to 18 months) in migraine patients with stable coronary artery disease in whom the use of triptans is not advisable. From the pooled analysis of the two Phase III Research Evaluating Migraine Prophylaxis Therapy studies of onabotulinumtoxin A (BOTOX) in chronic migraineurs, it clearly emerged that efficacy increases overtime (up to 56 weeks) and paralleled self-perceived improvement in quality of life. Effectiveness was also observed in patients with severely disabling headaches, who met criteria for triptan abuse and were refractory to several prophylactic treatments. Finally, combination of preventive pharmacological agents with different action mechanisms may be the next frontier in therapeutic advancements for treating migraine. Summary: Although triptans are safe and well tolerated, CGRP antagonists may be an option for nonresponsive patients or those in whom the use of triptans is not advisable. New drugs and combinations of old therapeutic options may help patients with severe forms of headache.

KW - Acute

KW - Migraine

KW - Preventive

KW - Review

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84860715051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860715051&partnerID=8YFLogxK

U2 - 10.1097/SPC.0b013e3283521dc3

DO - 10.1097/SPC.0b013e3283521dc3

M3 - Article

C2 - 22406987

AN - SCOPUS:84860715051

VL - 6

SP - 177

EP - 182

JO - Current Opinion in Supportive and Palliative Care

JF - Current Opinion in Supportive and Palliative Care

SN - 1751-4258

IS - 2

ER -